CD137 ligand (CD137L) has emerged as a powerful regulator of myelopoiesis that links emergency situations, such as infections, to the generation of additional myeloid cells, and to their activation and maturation. CD137L is expressed on the cell surface of hematopoietic stem and progenitor cells (HSPC) and antigen presenting cells (APC) as a transmembrane protein. The signaling of CD137L into HSPC induces their proliferation and differentiation to monocytes and macrophages, and in monocytes CD137L signaling induces differentiation to potent dendritic cells (DC). CD137L signaling is initiated by CD137 which is expressed by T cells, once they become activated. Some of these activated, CD137-expressing T cells migrate from the site of infection to the bone marrow where they interact with HSPC to induce myelopoiesis, or they induce monocyte to DC differentiation locally at the site of infection. Therapeutically, induction of CD137L signaling can be utilized to reinitiate myeloid differentiation in acute myeloid leukemia cells, and to generate potent DC for immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.3109/08830185.2014.921163DOI Listing

Publication Analysis

Top Keywords

cd137l signaling
16
site infection
8
cd137l
7
cells
7
signaling
5
regulation myelopoiesis
4
myelopoiesis cd137l
4
signaling cd137
4
cd137 ligand
4
ligand cd137l
4

Similar Publications

MD Simulation Reveals a Trimerization-Enhanced Interaction of CD137L with CD137.

Int J Mol Sci

February 2025

School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510006, China.

CD137 is a prominent costimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily that activates T cells through a complex bidirectional signaling process involving CD137L. The clinical value of immunotherapies underscores the potential of CD137L/CD137 as an effective target for boosting antitumor immune responses; however, the intricate mechanisms governing these interactions have not been fully elucidated. Herein, we constructed various oligomeric states of CD137L (monomeric, dimeric, and trimeric CD137L) and explored their interactions with CD137 using molecular dynamics simulations.

View Article and Find Full Text PDF

Despite the introduction of new drugs, multiple myeloma (MM) still remains incurable. We previously reported that CD34 MM cells, which are clonogenic and self-renewing, are therapy-resistant and persist as a major component of minimal residual disease, expanding during relapse. To investigate the effects of immunotherapies such as immune-checkpoint inhibitors, CAR-T therapy, and bispecific antibodies on CD34 MM cells, we analyzed immune profiles of both MM cells and T cells from MM patients using microarrays and flow cytometry.

View Article and Find Full Text PDF

Background: High-risk neuroblastoma (HR-NBL) is an aggressive tumor of the sympathetic nervous system with high risk of relapse and poor overall survival. Allogeneic hematopoietic cell transplant (allo-HCT) has been used previously in HR-NBL patients; however, graft-versus-host-disease (GVHD) and disease progression have limited clinical application. Ex-vivo stimulated allogeneic natural killer (NK) cells represent a potential approach to enhance the graft-versus-tumor (GVT) effect without exacerbation of GVHD but have not shown efficacy in NBL.

View Article and Find Full Text PDF

Protective Effect of CD137 Deficiency Against Postinfarction Cardiac Fibrosis and Adverse Cardiac Remodeling by ERK1/2 Signaling Pathways.

J Cardiovasc Pharmacol

May 2024

Department of Cardiology, Affiliated Hospital and Institute of Cardiovascular Diseases, Jiangsu University, Zhenjiang, China; and.

Myocardial fibrosis, a common complication of myocardial infarction (MI), is characterized by excessive collagen deposition and can result in impaired cardiac function. The specific role of CD137 in the development of post-MI myocardial fibrosis remains unclear. Thus, this study aimed to elucidate the effects of CD137 signaling using CD137 knockout mice and in vitro experiments.

View Article and Find Full Text PDF
Article Synopsis
  • Anxiety and cognitive dysfunction are common outcomes in patients with sepsis-associated encephalopathy (SAE), linked to inflammatory signals from microglia during infections.
  • * The study explored the role of the CD137 receptor/ligand system in modulating microglial function and its impact on neurological symptoms associated with SAE using a mouse model exposed to bacterial components.
  • * Results indicated that blocking CD137L with specific antibodies reduced inflammation and improved anxiety-like behavior and cognitive performance in mice with SAE.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!